Benitec Biopharma Inc.
BNTC
$14.61
-$0.33-2.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -22.12% | 1.81% | -2.12% | -11.19% | -8.63% |
| Total Depreciation and Amortization | 9.82% | 4.13% | -2.49% | -9.97% | -6.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 628.63% | 226.42% | 375.71% | 82.64% | 1.21% |
| Change in Net Operating Assets | 484.57% | -164.52% | -106.53% | 64.43% | 91.15% |
| Cash from Operations | 7.61% | -20.39% | -4.68% | -7.72% | -7.63% |
| Capital Expenditure | 90.00% | -19,000.00% | -17,800.00% | -17,800.00% | -1,284.62% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 90.00% | -19,000.00% | -17,800.00% | -17,800.00% | -1,284.62% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 166.89% | 166.89% | 109.48% | 313.34% | 72.90% |
| Repurchase of Common Stock | -23,156.41% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1,281.33% | 2.46% | 2.53% | -213.16% | -56.50% |
| Cash from Financing | 286.34% | 184.71% | 121.23% | 324.78% | 74.57% |
| Foreign Exchange rate Adjustments | 811.11% | 655.56% | -231.82% | -101.94% | -97.39% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,078.90% | 489.17% | 350.46% | 3,154.16% | 464.95% |